The prospective economic impact of once-monthly paliperidone palmitate versus oral atypical antipsychotics in Medicaid patients with schizophrenia.

CONCLUSION: Over 12 months, pharmacy costs associated with switching patients from OAAs to PP1M were offset by reduced relapse rates and schizophrenia-related healthcare expenditures, with earlier use of PP1M projected to generate greater cost savings. PMID: 30526125 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research